Should I buy Exelon (EXC) stock or is it too late?
⭐ The most reliable of them, either direction: Argus Research — 63% of its targets hit on this sector (80 calls tested). It aims for $49 (+16 %), call made on September 23, 2026, maturing on September 23, 2027 (21 d ago).
Firm-by-firm track record on Exelon
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 78 % | +10.3 % | 9 | $51 +20% |
| Barclays | 85 % | +9.9 % | 13 | $49 +16% |
| Morgan Stanley | 55 % | +8.3 % | 42 | $50 +18% |
| JP Morgan | 71 % | +7.8 % | 7 | $53 +25% |
| BMO Capital | 60 % | +2.3 % | 10 | $49 +16% |
| Citigroup | 62 % | +1.4 % | 8 | $58 +37% |
| Keybanc | 50 % | +1.3 % | 10 | $41 -3% |
| Wells Fargo | 38 % | -6.8 % | 8 | $53 +25% |
✅ Reasons to believe
- Median price target $49, i.e. +16% from the current price ($42).
- The most reliable firm on EXC, Barclays (85% hit rate, 13 scored calls), targets $49 (call made on April 17, 2026, maturing on April 17, 2027) (+16%) in its most recent call, and $52 (call made on October 14, 2025, maturing on October 14, 2026) (+23%) in the one coming due soonest.
- Pays a dividend (3.5% yield), raised for 10 years — regular income on top of potential upside.
- Reasonable valuation (P/E ~16) relative to its sector.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 9 ratings, 8 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on EXC
Median target $49 (+16%) · 9 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Exelon now?
We won't decide for you. The facts: 11% of analysts rate it a buy, median target $49 (+16%), and Barclays (most reliable on EXC, 85%) targets $49. Weigh that against valuation (P/E ~16). This is not personalized advice.
Is it too late to invest in Exelon?
Not according to analysts: the median target ($49) is still +16% above the current price ($42) (most reliable on EXC: Barclays, 85%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Exelon still worth investing in?
It depends on the gap between the price ($42) and its estimated value: analysts target $49 on median (+16%), with 11% buys (most reliable on EXC: Barclays, 85%). Cross-check with their real reliability on EXC and the cautions above. Information, not advice.
What's the main risk in buying EXC?
The consensus is not unanimous: of 9 ratings, 8 are neutral.
→ Go deeper: the full Exelon profile (consensus, analyst reliability, price target, performance).